Keloid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Keloid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A7544

Market Overview:

The 7 major keloid markets reached a value of USD 242.8 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 356.3 Million by 2035, exhibiting a growth rate (CAGR) of 3.53% during 2025-2035.

Report Attribute
Key Statistics
Base Year 
2024
Forecast Years  2025-2035
Historical Years 
2019-2024
Market Size in 2024
USD 242.8 Million
Market Forecast in 2035
USD 356.3 Million
Market Growth Rate 2025-2035
3.53%
Prevalence Cases in 2024 19,535,019
Prevalence Cases in 2035 21,113,350


The keloid market has been comprehensively analyzed in IMARC's new report titled "Keloid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Keloid refers to a medical condition that occurs when an excess amount of collagen, a protein that forms the connective tissue in the skin, is produced during the healing process of a wound or injury. The excess collagen results in the development of raised, thick, and often irregular scar that extends beyond the borders of the original wound. These scars may range in size from a few millimeters to several centimeters and can be pink, red, brown, or flesh-colored. Keloids may be itchy or tender, and they can cause discomfort or pain. In addition to physical symptoms, they can also lead to emotional distress due to their unsightly appearance and the social stigma associated with them. The diagnosis of the ailment is usually based on a physical exam and medical history. A dermatologist or healthcare provider will typically examine the keloid and surrounding skin for characteristic signs, such as raised and shiny scars that extend beyond the original wound site. The doctor may also enquire about the patient's medical history, including previous injuries or surgeries, and family history of keloids. In some cases, a biopsy may be performed to confirm the diagnosis and rule out other skin conditions. Numerous imaging tests, such as ultrasound, MRI, CT scans, etc., are utilized to evaluate the extent of the keloid.

Keloid Market

The increasing occurrences of various skin injuries, including surgical scars, burns, acne, deep cuts, etc., are primarily driving the keloid market. Besides this, the growing prevalence of several cosmetic procedures, such as piercings and tattoos, which can potentially result in keloid formation, is also augmenting the market growth. Furthermore, the widespread adoption of corticosteroid injections for reducing the size of the keloid, making them less noticeable, is creating a positive outlook for the market. Apart from this, the inflating demand for cryotherapy, which involves freezing the keloids with liquid nitrogen, thereby causing the keloid tissue to break down and eventually fall off, is acting as another significant growth-inducing factor. Additionally, the introduction of advanced diagnostic techniques, such as multiphoton microscopy and optical coherence tomography, since they provide high-resolution images of the skin and can help identify the location as well as the extent of keloids, is also bolstering the market growth. Moreover, the emerging popularity of radiofrequency ablation on account of its numerous benefits over traditional surgical excision, including reduced scarring, improved function, and fewer complications, is expected to drive the keloid market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the keloid market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for keloid and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the keloid market in any manner.

Time Period of the Study

  • Base Year: 2024
  • Historical Period: 2019-2024
  • Market Forecast: 2025-2035


Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the keloid market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the keloid market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs
     

Competitive Landscape:

This report also provides a detailed analysis of the current keloid marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Kenalog-10 Injection (Triamcinolone Acetonide) Bristol-Myers Squibb
Aristospan (Triamcinolone Hexacetonide) Sandoz
Aldara (Imiquimod 5% cream)  3M Health Care
Adrucil (5-Fluorouracil) Teva Pharmaceuticals
Verelan (Verapamil) UCB
Jelmyto (Mitomycin C) UroGen Pharma
Bleo 15k (Bleomycin) Amneal Biosciences
Botox (onabotulinumtoxinA)/botulinum toxin Allergan
Tranilast (Rizaben) Kissei Pharmaceuticals
TOP-N44 Topadur Pharma
INV 001 Innovo Therapeutics
AIV001 AiViva BioPharma
STP 705 Sirnaomics


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the keloid market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
  • What was the country-wise size of the keloid market across the seven major markets in 2024 and what will it look like in 2035?
  • What is the growth rate of the keloid market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (​2019-2035​) of keloid across the seven major markets?
  • What is the number of prevalent cases (​2019-2035​) of keloid by age across the seven major markets?
  • What is the number of prevalent cases (​2019-2035​) of keloid by gender across the seven major markets?
  • How many patients are diagnosed (​2019-2035​) with keloid across the seven major markets?
  • What is the size of the keloid patient pool (2019-2024) across the seven major markets?
  • What would be the forecasted patient pool (2025-2035) across the seven major markets?
  • What are the key factors driving the epidemiological trend of keloid?
  • What will be the growth rate of patients across the seven major markets?
     

Keloid: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for keloid drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the keloid market?
  • What are the key regulatory events related to the keloid market?
  • What is the structure of clinical trial landscape by status related to the keloid market?
  • What is the structure of clinical trial landscape by phase related to the keloid market?
  • What is the structure of clinical trial landscape by route of administration related to the keloid market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Keloid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials